Panelists discuss how progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF), though distinct in ...

New tools, treatment options, and precision medicine developments are leading to better quality of life and survival for ...

Novel oral agent nerandomilast slowed lung capacity decline in patients with non-idiopathic pulmonary fibrosis (IPF) ...

Panelists discuss how idiopathic pulmonary fibrosis (IPF), a progressive and often fatal interstitial lung disease, presents ...

Results presented at this year’s American Thoracic Society International Conference showed that the trials met their primary ...

Future Market Insights NEWARK, DE, UNITED STATES, May 27, 2025 /EINPresswire.com/ -- The global progressive fibrosing interstitial lung disease (PF-ILD) treatment market is witnessing robust growth, ...

A new drug for pulmonary fibrosis has reduced disease progression by more than 50% over a 52-week treatment in two clinical ...

The investigative phosphodiesterase 4B inhibitor appears better than placebo at protecting against decline in lung function ...

Data from the FIBRONEER-IPF and FIBRONEER-ILD studies, published in The New England Journal of Medicine, highlight ...

Mold thrives where moisture lingers. Spores can flourish after floods, heavy rains, or the unseen drip of a leaky pipe, ...